newsfilter
← Earnings
Earnings Releases·

Xtant Medical — Third Quarter 2026 Earnings Summary

  • Total revenue fell 27% year-over-year to $24.3 million, driven by the absence of divested assets and wound care licensing revenue, though biologics revenue rose 13% to $19.3 million; net loss widened to $3.6 million compared to a $1.3 million profit in the prior year period.
  • Gross margin contracted to 56.3% from 66.1% due to the cessation of high-margin licensing revenue and unfavorable sales mix, while operating expenses decreased to $16.7 million.
  • The company has withdrawn its full-year 2026 guidance and suspended revised guidance while the Board conducts a strategic review evaluating operational improvements, capital structure changes, and potential transactions.
  • Liquidity remains sufficient for the next 12 months with $7.8 million in cash and $2.1 million available under the revolving credit facility, despite a year-to-date cash decline from $17.1 million.
  • Management expressed disappointment over missing guidance for the second consecutive quarter, citing the need to improve execution and maximize stockholder value through the ongoing strategic review.
Company
XTANT MEDICAL HOLDINGS INC
Sector
Healthcare
Industry
Medical Devices